Frequency of receiving antiviral medications in patients who died following COVID-19 disease

Ezat Hesni; Heydar Ali Balou; Kourosh Delpasand; Zahra Taheri; Morteza Rahbar Taromsari; Saman Maroufizadeh; Mahshad Dehghan; Mahdis Parhizkar Astaneh

doi:10.61882/jcbior.4.3.236

Authors

Ezat Hesni Razi Clinical Research Development Unit, Razi, Hospital, Guilan University of Medical Sciences, Rasht, Iran
Heydar Ali Balou Razi Clinical Research Development Unit, Razi, Hospital, Guilan University of Medical Sciences, Rasht, Iran
Kourosh Delpasand Razi Clinical Research Development Unit, Razi, Hospital, Guilan University of Medical Sciences, Rasht, Iran http://orcid.org/0000-0001-6842-3374
Zahra Taheri Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
Morteza Rahbar Taromsari Razi Clinical Research Development Unit, Razi, Hospital, Guilan University of Medical Sciences, Rasht, Iran
Saman Maroufizadeh Razi Clinical Research Development Unit, Razi, Hospital, Guilan University of Medical Sciences, Rasht, Iran
Mahshad Dehghan Razi Clinical Research Development Unit, Razi, Hospital, Guilan University of Medical Sciences, Rasht, Iran
Mahdis Parhizkar Astaneh Razi Clinical Research Development Unit, Razi, Hospital, Guilan University of Medical Sciences, Rasht, Iran

DOI:

https://doi.org/10.61882/jcbior.4.3.236

Keywords:

COVID-19, SARS-CoV-2, Antiviral medication, Remdesivir, Hospitalization

Abstract

Various antiviral medications have been used during the Coronavirus disease 2019 (COVID-19) pandemic, however, there is no promising result on the effectiveness of many of these medications, their side effects, and their association with death in patients. This study aimed to investigate the frequency of receiving antiviral medications in patients who died due to COVID-19 disease. In this cross-sectional study, the demographical data and clinical characteristics of 1477 deceased patients with COVID-19 who were referred to Razi Hospital, Rasht, Iran, from 2018 to 2019, were collected from the hospital archive. The data included age, gender, medical insurance, hospitalization in the intensive care unit (ICU), O2 saturation, a history of underlying disease, and antiviral medications (Remdesivir, Oseltamivir, IFN-β-1a, and Lopinavir/Ritonavir). Due to our results the mean age of deceased patients was 64.8 years old. A total number of 764 patients were males. About 664 patients received Remdesivir, 388 patients received Interferon-beta-1a (IFNβ-1a), 186 patients received Oseltamivir, 169 patients received Lopinavir/Ritonavir, and 475 patients did not take any antiviral medications. Also, 609 people (41.2%) received one, 381 people (25.8%) received two, and 12 people (8%) received three antiviral medications. The results of the present study showed that in one-third of the cases, no antiviral medications were taken and the most frequent antiviral medication among patients was Remdesivir.

References

1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. http://dx.doi.org/10.1016/j.ijantimicag.2020.105924 http://www.ncbi.nlm.nih.gov/pubmed/32081636

2. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses-a statement of the Coronavirus Study Group. BioRxiv. 2020. http://dx.doi.org/10.1101/2020.02.07.937862

3. Tavakoli A, Vahdat K, Keshavarz M. Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century. Iranian South Med J. 2020;22(6):432-50. http://dx.doi.org/10.29252/ismj.22.6.432

4. Sun P, Qie S, Liu Z, Ren J, Xi J. Clinical characteristics of 50404 patients with 2019-nCoV infection. MedRxiv. 2020:2002-20. http://dx.doi.org/10.1101/2020.02.18.20024539

5. Halaji M, Heiat M, Faraji N, Ranjbar R. Epidemiology of COVID-19: An updated review. J Res Med Sci. 2021;26:82. http://dx.doi.org/10.4103/jrms.JRMS_506_20 http://www.ncbi.nlm.nih.gov/pubmed/34759999

6. Yaghubi T, Shakoori V, Nasiri S, Keivan M, Tavakol C, Ahanjide S, et al. Clinical characteristics and outcomes of COVID-19 patients with a history of cardiovascular disease. J Curr Biomed Reports. 2022;3(1):36-42. http://dx.doi.org/10.52547/jcbior.3.1.36

7. Yaghubi Kalurazi T, Shakoori V, Nasiri S, Alavi Foumani A, Hesni E, Mahfoozi L, et al. Clinical characteristics and laboratory findings of patients with COVID-19 in Rasht, Iran. J Curr Biomed Reports. 2022;3(2):91-7. http://dx.doi.org/10.52547/JCBioR.3.2.91

8. Zeinali T, Faraji N, Joukar F, Khan Mirzaei M, Kafshdar Jalali H, Shenagari M, et al. Gut bacteria, bacteriophages, and probiotics: Tripartite mutualism to quench the SARS-CoV2 storm. Microb Pathog. 2022;170:105704. http://dx.doi.org/10.1016/j.micpath.2022.105704 http://www.ncbi.nlm.nih.gov/pubmed/35948266

9. Simsek Yavuz S, Unal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020;50(SI-1):611-9. http://dx.doi.org/10.3906/sag-2004-145 http://www.ncbi.nlm.nih.gov/pubmed/32293834

10. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813-26. http://dx.doi.org/10.1056/NEJMoa2007764 http://www.ncbi.nlm.nih.gov/pubmed/32445440

11. Chiba S. Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19. Wien Klin Wochenschr. 2021;133(7-8):292-7. http://dx.doi.org/10.1007/s00508-020-01780-0 http://www.ncbi.nlm.nih.gov/pubmed/33296027

12. Zendehdel A, Bidkhori M, Ansari M, Jamalimoghaddamsiyahkali S, Asoodeh A. Efficacy of oseltamivir in the treatment of patients infected with Covid-19. Ann Med Surg (Lond). 2022;77:103679. http://dx.doi.org/10.1016/j.amsu.2022.103679 http://www.ncbi.nlm.nih.gov/pubmed/35531426

13. Tan Q, Duan L, Ma Y, Wu F, Huang Q, Mao K, et al. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. Bioorg Chem. 2020;104:104257. http://dx.doi.org/10.1016/j.bioorg.2020.104257 http://www.ncbi.nlm.nih.gov/pubmed/32927129

14. Verdugo-Paiva F, Acuña P, Sola I, Rada G. Lopinavir-ritonavir for COVID-19: A living systematic review. Medwave. 2020:e7967-e. http://dx.doi.org/10.1101/2020.09.27.20202754

15. Qomara WF, Primanissa DN, Amalia SH, Purwadi FV, Zakiyah N. Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review. Int J Gen Med. 2021;14:8557-71. http://dx.doi.org/10.2147/IJGM.S332458 http://www.ncbi.nlm.nih.gov/pubmed/34849001

16. Jalkanen J, Hollmen M, Jalkanen S. Interferon beta-1a for COVID-19: critical importance of the administration route. Crit Care. 2020;24(1):335. http://dx.doi.org/10.1186/s13054-020-03048-5 http://www.ncbi.nlm.nih.gov/pubmed/32532353

17. Payandemehr P, Azhdarzadeh M, Bahrami-Motlagh H, Hadadi A, Najmeddin F, Shahmirzaei S, et al. Interferon beta-1a as a candidate for COVID-19 treatment; an open-label single-arm clinical trial. Front Emerg Med. 2020;4(2s):e51-e.

18. Dastan F, Nadji SA, Saffaei A, Marjani M, Moniri A, Jamaati H, et al. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. Int Immunopharmacol. 2020;85:106688. http://dx.doi.org/10.1016/j.intimp.2020.106688 http://www.ncbi.nlm.nih.gov/pubmed/32544867

19. Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(12):1365-76. http://dx.doi.org/10.1016/S2213-2600(21)00384-2 http://www.ncbi.nlm.nih.gov/pubmed/34672949

20. Jomah S, Asdaq SMB, Al-Yamani MJ. Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. J Infect Public Health. 2020;13(9):1187-95. http://dx.doi.org/10.1016/j.jiph.2020.07.013 http://www.ncbi.nlm.nih.gov/pubmed/32773212

21. Saqrane S, El Mhammedi MA, Lahrich S, Laghrib F, El Bouabi Y, Farahi A, et al. Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections. J Infect Public Health. 2021;14(5):655-60. http://dx.doi.org/10.1016/j.jiph.2021.02.006 http://www.ncbi.nlm.nih.gov/pubmed/33857725

22. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. http://dx.doi.org/10.1038/s41467-019-13940-6 http://www.ncbi.nlm.nih.gov/pubmed/31924756

23. Pruijssers AJ, George AS, Schafer A, Leist SR, Gralinksi LE, Dinnon KH, 3rd, et al. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020;32(3):107940. http://dx.doi.org/10.1016/j.celrep.2020.107940 http://www.ncbi.nlm.nih.gov/pubmed/32668216

24. Sodeifian F, Nikfarjam M, Kian N, Mohamed K, Rezaei N. The role of type I interferon in the treatment of COVID-19. J Med Virol. 2022;94(1):63-81. http://dx.doi.org/10.1002/jmv.27317 http://www.ncbi.nlm.nih.gov/pubmed/34468995

25. Ceramella J, Iacopetta D, Sinicropi MS, Andreu I, Mariconda A, Saturnino C, et al. Drugs for COVID-19: An Update. Molecules. 2022;27(23). http://dx.doi.org/10.3390/molecules27238562 http://www.ncbi.nlm.nih.gov/pubmed/36500655